Combination

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to December 3, 2023

Retrieved on: 
Tuesday, October 31, 2023
Transfer, Combination, VSAC, Acquisition, Exercise, Extension, Security (finance)

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by November 3, 2023 (the “Extension”).

Key Points: 
  • MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by November 3, 2023 (the “Extension”).
  • In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This will be the first of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

Retrieved on: 
Tuesday, October 31, 2023
Combination, Patent, Chronic pain, TEL, IP Australia, Legislation, Pain, Market, Route of administration, Opioid, Disorder, Intrathecal administration, Patient, Central nervous system, Pharmaceutical industry, Anesthesia

The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.
  • The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth.
  • At the same time, opioid abuse and addiction has been a global growing epidemic for more than a decade.
  • "The fact that SciSparc's number of granted patents continues to grow is proof recognizing the innovation that characterizes the technologies in the Company's pipeline.

Enhanc3D Genomics Expands Leadership Team With the Appointment of Hazel Jones as Chief Operating Officer

Retrieved on: 
Monday, November 6, 2023
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, 3D, Combination, Genomics, AstraZeneca, Integrated business planning, Bachelor of Science, Doctor of Philosophy, Database, GWAS, University, Cancer research, Gene, Genome-wide association study, Algorithm, Clinical data management, Patient, Diagnosis, DNA, Nursing, Antibiotics, Biochemistry, Pharmacology

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.
  • Hazel has over 10 years of senior leadership experience in oncology research.
  • Prior to joining Enhanc3D Genomics, Hazel held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D.
  • I am delighted to welcome Hazel to the team.”
    Dr Hazel Jones, Chief Operating Officer, Enhanc3D Genomics, added: “I’m delighted to join the team at such an exciting stage of the Company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”
    For more information about Enhanc3D Genomics, please visit: www.enhanc3dgenomics.com

Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Combination, Multiple myeloma, Lenalidomide, Safety, Termination, Therapy, Patient, Pharmaceutical industry

Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell Acquisition Corp.

Key Points: 
  • Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell Acquisition Corp.
  • I (NASDAQ: HWEL) (“Healthwell”) today that the Company had elected to terminate the business combination agreement among Starton, Healthwell and the other parties thereto dated as of April 27, 2023, as amended (the “Combination Agreement”), effective immediately.
  • The conditions to the closing of the initial business combination and subsequent amendments were not satisfied or waived by the outside date of November 3 2023 (the “Termination”).
  • “Over the last several months, Starton has taken significant, critical steps forward in its clinical development,” said Pedro Lichtinger, Chairman and CEO of Starton Therapeutics.

Renesas’ New Ultra-High Performance MCUs are Industry’s First Based on Arm Cortex-M85 Processor

Retrieved on: 
Tuesday, October 31, 2023
Semiconductor, Engineering, Technology, Manufacturing, Software, Hardware, Cortex, ECC, CTI Electronics Corporation, Octal, Architecture, XIP, TCM, FIPS, AI, Winning Combination, Memory, Internet of things, ARM Cortex-A53, Intelligence, PSA, NIST, MCU, RA, Feminism and modern architecture, Internet, PLC, ARM Cortex-M, Ecosystem, Machine learning, Embedded, Silicon, Combination, Smartglasses, CAVP, Reality, Center for Advanced Security Research Darmstadt, Family, Arm, ARM architecture family, Comparison of multi-paradigm programming languages, Multimedia, Mantra, DSP, Senior, FSP, MPU, Coremark, SE, ML, BSP, Video game, Medical device, Renesas Electronics, Helium, Ethernet

The new RA8 Series MCUs are the industry’s first to implement the Arm® Cortex®-M85 processor, enabling the new devices to deliver industry-leading 6.39 CoreMark/MHz1 performance.

Key Points: 
  • The new RA8 Series MCUs are the industry’s first to implement the Arm® Cortex®-M85 processor, enabling the new devices to deliver industry-leading 6.39 CoreMark/MHz1 performance.
  • This level of performance will allow system designers to use the RA MCUs in applications that previously required microprocessors (MPUs).
  • The new series is part of Renesas’ popular RA Family of MCUs based on Arm Cortex processors.
  • View the full release here: https://www.businesswire.com/news/home/20231031195413/en/
    The new RA8 Series MCUs deploy Arm Helium™ technology, Arm’s M-Profile Vector Extension that provides up to a 4X performance boost for digital signal processor (DSP) and machine learning (ML) implementations versus MCUs based on the Arm Cortex-M7 processor.

X-energy and Ares Acquisition Corporation Mutually Agree to Terminate Business Combination Agreement

Retrieved on: 
Tuesday, October 31, 2023
Finance, Alternative Energy, Energy, Professional Services, Nuclear, Transfer, Combination, U.S. Department of Defense Strategy for Operating in Cyberspace, NYSE, New York Stock Exchange, Accounting, ARES, Energy Northwest, Wind, Acquisition, Final, Entrepreneurship, Electric Bond and Share Company v. Securities and Exchange Commission, Texas Gulf Coast, Redemption, Finance Secretary (India), Growth, Trust, Partner, United States Department of Energy, Dow, Interest on Lawyer Trust Accounts, Texas Gulf Coast Regional Airport, AAC, Defense, Cryptocurrency, Management, Security (finance), Article

X-Energy Reactor Company, LLC (“X-energy”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (NYSE: AAC) (“AAC”), a publicly-traded special purpose acquisition company, announced today that they have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”), effective immediately.

Key Points: 
  • X-Energy Reactor Company, LLC (“X-energy”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, and Ares Acquisition Corporation (NYSE: AAC) (“AAC”), a publicly-traded special purpose acquisition company, announced today that they have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination Agreement”), effective immediately.
  • Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the business combination agreement.
  • In view of the termination of the Business Combination Agreement, AAC determined that it will not be able to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (as amended, the “Articles”).
  • As of November 6, 2023, AAC will cease all operations except those required to wind up AAC’s business.

Syntax and Beyond Technologies Complete Acquisition Deal, Officially Join Forces

Retrieved on: 
Thursday, November 2, 2023
Internet of things, Combination, Partner (business rank), Local, Organization, Acquisition, Specialization, Public sector, Ecosystem, Partnership, SAP, Natural Resources, Consultant, Management, Syntax

MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems, a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction. The deal, which was announced October 3, 2023, brings Beyond a professional services firm specializing in SAP® solution integration and business performance optimization into the Syntax family.

Key Points: 
  • MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems , a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction.
  • "Bringing the Syntax and Beyond teams together is directly aligned to our strength in delivering industry-first capabilities.
  • In June 2021, Syntax acquired Illumiti, a Syntax Company, an integration and management consultancy firm.
  • "Syntax's acquisition of Beyond Technologies represents the continued commitment to client success, ecosystem partnership, good corporate citizenship and being an employer of choice for technology talent.

Syntax and Beyond Technologies Complete Acquisition Deal, Officially Join Forces

Retrieved on: 
Thursday, November 2, 2023
Internet of things, Combination, Partner (business rank), Local, Organization, Acquisition, Specialization, Public sector, Ecosystem, Partnership, SAP, Natural Resources, Consultant, Management, Syntax

MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems, a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction. The deal, which was announced October 3, 2023, brings Beyond a professional services firm specializing in SAP® solution integration and business performance optimization into the Syntax family.

Key Points: 
  • MONTRÉAL, Nov. 2, 2023 /PRNewswire/ -- Syntax Systems , a leading global technology solutions and services provider for cloud application implementation and management, and Montréal-based Beyond Technologies today announced the successful completion of the acquisition transaction.
  • "Bringing the Syntax and Beyond teams together is directly aligned to our strength in delivering industry-first capabilities.
  • In June 2021, Syntax acquired Illumiti, a Syntax Company, an integration and management consultancy firm.
  • "Syntax's acquisition of Beyond Technologies represents the continued commitment to client success, ecosystem partnership, good corporate citizenship and being an employer of choice for technology talent.

Two Day Online Development of Combination Pharma Products Training Course: Focus on Critical Interactions - Navigating GMP and Quality in Pharma (February 12-13, 2024) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Training, Education, Combination, Good manufacturing practice, GMP, European, CTD, Research, R, Common Technical Document, Plasma protein binding, Medical device, EU

The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Development of Combination Products: Critical Interactions Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • This program provides valuable insights into crafting an effective regulatory strategy while addressing crucial aspects of Good Manufacturing Practices (GMP) and quality processes.
  • Our interactive seminar serves as a guide to understanding both the European Union (EU) and US approaches to handling drug/device and device/drug combination products.
  • Furthermore, this seminar will emphasize the interconnectedness of quality, regulatory affairs, research and development (R&D), and production functions.

Foundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations

Retrieved on: 
Thursday, October 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Combination, NCI, Foundation Medicine, MD, Doctor of Philosophy, National Cancer Institute, Alliance for Clinical Trials in Oncology, Partnership, Cancer, Drug combination, Bangladesh Technical Education Board, Pharmaceutical industry, Nursing, Medical imaging

Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.

Key Points: 
  • Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.
  • Foundation Medicine is one of nearly 40 participating Designated Laboratories, meaning that oncologists at participating ComboMATCH clinical sites may utilize their patients' FoundationOne®CDx commercial testing results to help determine their eligibility for ComboMATCH treatment trials.
  • ComboMATCH tests whether therapy selected in this manner to treat cancer may provide better patient outcomes than the current standard of care.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.